CY1120281T1 - Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail - Google Patents

Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail

Info

Publication number
CY1120281T1
CY1120281T1 CY20181100568T CY181100568T CY1120281T1 CY 1120281 T1 CY1120281 T1 CY 1120281T1 CY 20181100568 T CY20181100568 T CY 20181100568T CY 181100568 T CY181100568 T CY 181100568T CY 1120281 T1 CY1120281 T1 CY 1120281T1
Authority
CY
Cyprus
Prior art keywords
trail
single chain
receptor agonist
chain proteins
trail receptors
Prior art date
Application number
CY20181100568T
Other languages
English (en)
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Fritz G. BUCHANAN
Darren C. PHILLIPS
Susan E. LAPPE
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1120281T1 publication Critical patent/CY1120281T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)

Abstract

Παρέχονται στο παρόν συγκεκριμένες πρωτεΐνες αγωνιστές των υποδοχέων της TRAIL, νουκλεϊκά οξέα που τις κωδικοποιούν και μέθοδοι θεραπείας ενός υποκειμένου που πάσχει από μια νόσο ή διαταραχή σχετιζόμενη με την TRAIL. Οι πρωτεΐνες αγωνιστές των υποδοχέων της TRAIL που παρέχονται στο παρόν περιλαμβάνουν τρεις διαλυτούς τομείς της TRAIL και ένα θραύσμα Fc. Οι πρωτεΐνες αγωνιστές των υποδοχέων της TRAIL είναι ουσιαστικά μη συσσωματούμενες και είναι κατάλληλες για θεραπευτικές, διαγνωστικές ή/και ερευνητικές εφαρμογές.
CY20181100568T 2014-04-23 2018-05-25 Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail CY1120281T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (1)

Publication Number Publication Date
CY1120281T1 true CY1120281T1 (el) 2019-07-10

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100568T CY1120281T1 (el) 2014-04-23 2018-05-25 Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail

Country Status (37)

Country Link
US (4) US9908927B2 (el)
EP (2) EP3134430B1 (el)
JP (2) JP6523331B2 (el)
KR (2) KR20190135546A (el)
CN (2) CN111718424A (el)
AR (1) AR100168A1 (el)
AU (3) AU2015249649B2 (el)
BR (1) BR112016024515B1 (el)
CA (2) CA2946402C (el)
CL (1) CL2016002683A1 (el)
CR (1) CR20160516A (el)
CY (1) CY1120281T1 (el)
DK (1) DK3134430T3 (el)
DO (1) DOP2016000284A (el)
EC (1) ECSP16089579A (el)
ES (1) ES2672368T3 (el)
HR (1) HRP20180950T1 (el)
HU (1) HUE038914T2 (el)
IL (2) IL248244B (el)
LT (1) LT3134430T (el)
MA (2) MA45069A (el)
MX (2) MX2016013858A (el)
MY (1) MY181986A (el)
NO (1) NO2776305T3 (el)
PE (1) PE20170299A1 (el)
PH (1) PH12016502079B1 (el)
PL (1) PL3134430T3 (el)
PT (1) PT3134430T (el)
RS (1) RS57153B1 (el)
RU (1) RU2699285C2 (el)
SG (3) SG10201806465TA (el)
SI (1) SI3134430T1 (el)
TR (1) TR201806912T4 (el)
TW (2) TWI683825B (el)
UA (1) UA118286C2 (el)
UY (1) UY36095A (el)
WO (1) WO2015164588A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023646A2 (pt) * 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
WO2017068180A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
EP3423480A1 (en) * 2016-03-01 2019-01-09 The Board of Trustees of the University of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
JP2019518713A (ja) * 2016-03-16 2019-07-04 メリマック ファーマシューティカルズ インコーポレーティッド 癌療法のための改変ｔｒａｉｌ
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019517570A (ja) * 2016-06-13 2019-06-24 メリマック ファーマシューティカルズ インコーポレーティッド Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US11578315B2 (en) 2017-08-11 2023-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
WO2019178433A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2019178438A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
CZ308214B6 (cs) 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
DE602006009786D1 (de) 2005-04-15 2009-11-26 Rappaport Family Inst For Res Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CA2860950C (en) 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
CN102317314A (zh) * 2008-10-10 2012-01-11 阿纳福公司 结合trail-r1和trail-r2的多肽
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
AU2010206681A1 (en) * 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
EP2516458A1 (en) 2009-12-22 2012-10-31 Novartis AG Tetravalent cd47-antibody constant region fusion protein for use in therapy
EP2560684A4 (en) 2010-04-13 2013-11-20 Medimmune Llc FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
US9717803B2 (en) * 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
AU2013291982B2 (en) 2012-07-18 2017-01-12 Apogenix Ag Shortened CD95-Fc variants

Also Published As

Publication number Publication date
EP3134430B1 (en) 2018-03-21
NO2776305T3 (el) 2018-01-27
WO2015164588A1 (en) 2015-10-29
MX2016013858A (es) 2017-08-02
US9908927B2 (en) 2018-03-06
CN106459221B (zh) 2020-09-01
PH12016502079A1 (en) 2016-12-19
PL3134430T3 (pl) 2018-08-31
US20240174731A1 (en) 2024-05-30
CA2946402C (en) 2023-02-28
IL248244B (en) 2020-03-31
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
JP2017513503A (ja) 2017-06-01
TW201620928A (zh) 2016-06-16
PH12016502079B1 (en) 2016-12-19
AU2015249649B2 (en) 2018-10-04
CL2016002683A1 (es) 2017-07-07
CA2946402A1 (en) 2015-10-29
DOP2016000284A (es) 2017-02-15
CR20160516A (es) 2017-05-10
HUE038914T2 (hu) 2018-12-28
UA118286C2 (uk) 2018-12-26
PE20170299A1 (es) 2017-05-06
TW202024123A (zh) 2020-07-01
JP6523331B2 (ja) 2019-05-29
MX2019013587A (es) 2020-01-13
SG10201806465TA (en) 2018-08-30
PT3134430T (pt) 2018-04-20
HRP20180950T1 (hr) 2018-08-10
US20180222962A1 (en) 2018-08-09
JP2019162114A (ja) 2019-09-26
NZ725476A (en) 2023-09-29
MY181986A (en) 2021-01-18
BR112016024515B1 (pt) 2020-03-31
EP3134430A1 (en) 2017-03-01
DK3134430T3 (en) 2018-05-22
AU2015249649A1 (en) 2016-11-10
US20210040178A1 (en) 2021-02-11
MA39770A (fr) 2015-10-29
BR112016024515A2 (pt) 2017-10-10
IL248244A0 (en) 2016-11-30
ECSP16089579A (es) 2018-05-31
KR20170012257A (ko) 2017-02-02
RU2699285C2 (ru) 2019-09-04
MA45069A (fr) 2019-04-03
SI3134430T1 (en) 2018-05-31
SG11201608767XA (en) 2016-11-29
US20150337027A1 (en) 2015-11-26
TWI747178B (zh) 2021-11-21
KR20190135546A (ko) 2019-12-06
AR100168A1 (es) 2016-09-14
EP3366699A1 (en) 2018-08-29
ES2672368T3 (es) 2018-06-14
RS57153B1 (sr) 2018-07-31
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
TWI683825B (zh) 2020-02-01
JP6714751B2 (ja) 2020-06-24
AU2020202247A1 (en) 2020-04-23
TR201806912T4 (tr) 2018-06-21
UY36095A (es) 2015-10-30
KR102079919B1 (ko) 2020-02-24
AU2018271369A1 (en) 2018-12-20
RU2016145608A (ru) 2018-05-28
LT3134430T (lt) 2018-05-10
IL272612A (en) 2020-03-31
SG10202111785VA (en) 2021-12-30
RU2016145608A3 (el) 2018-12-26

Similar Documents

Publication Publication Date Title
CY1120281T1 (el) Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1122188T1 (el) Θεραπευτικη αντιμετωπιση της προοδευτικης οστεοποιους ινοδυσπλασιας
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CY1122528T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
CO2018010475A2 (es) Moléculas de unión a bcma y métodos de uso de las mismas
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
DK3500593T3 (da) Ukendte t-cellereceptorer og immunterapi under anvendelse deraf
DK3221355T3 (da) Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
DK3293202T3 (da) Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
AR098408A1 (es) Anticuerpos específicos para fcrn
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1